S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
66,000% upside on tiny biotech? (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Laser breakthrough could send stock soaring 2,467% (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
Laser breakthrough could send stock soaring 2,467% (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Forecast, Price & News

$13.38
+0.39 (+3.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$12.90
$13.48
50-Day Range
$11.54
$14.86
52-Week Range
$10.84
$25.77
Volume
730,299 shs
Average Volume
916,708 shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.14

Day One Biopharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
215.0% Upside
$42.14 Price Target
Short Interest
Bearish
20.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$63,562 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.45) to ($2.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

855th out of 968 stocks

Pharmaceutical Preparations Industry

399th out of 439 stocks


DAWN stock logo

About Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Price History

DAWN Stock News Headlines

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down to $14.64
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
The Latest Analyst Ratings for Day One Biopharmaceutical
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Day One Biopharmaceuticals (DAWN) Gets a Buy from H.C. Wainwright
JonesTrading Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)
Day One Biopharmaceuticals (DAWN) Gets a Buy from J.P. Morgan
FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc
Diving Into Day One Biopharmaceuticals
Analyst Ratings for Day One Biopharmaceutical
See More Headlines
Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DAWN Company Calendar

Last Earnings
8/07/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DAWN
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.14
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+215.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-142,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.51 per share

Miscellaneous

Free Float
79,320,000
Market Cap
$1.16 billion
Optionable
Not Optionable
Beta
-2.01
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Jeremy Bender M.B.A. (Age 51)
    Ph.D., CEO, Pres & Director
    Comp: $900k
  • Dr. Samuel C. Blackman M.D. (Age 54)
    Ph.D., Co-Founder and Head of R&D
    Comp: $651k
  • Mr. Charles N. York II (Age 46)
    COO, CFO & Sec.
    Comp: $715k
  • Dr. Mike Preigh Ph.D.
    Chief of Technology Operations
  • Mr. Adam Dubow (Age 56)
    Gen. Counsel
  • Ms. Jaa Roberson
    Chief People Officer
  • Dr. Davy Chiodin Ph.D.
    Pharm.D., Chief Devel. Officer
  • Ms. Lauren Merendino M.B.A. (Age 47)
    Chief Commercial Officer
  • Prof. Raphael F. Rousseau M.D. (Age 54)
    Ph.D., Chief Medical Officer













DAWN Stock - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings
or view top-rated stocks.

What is Day One Biopharmaceuticals' stock price forecast for 2023?

8 Wall Street analysts have issued 12-month price objectives for Day One Biopharmaceuticals' stock. Their DAWN share price forecasts range from $34.00 to $54.00. On average, they predict the company's share price to reach $42.14 in the next year. This suggests a possible upside of 215.0% from the stock's current price.
View analysts price targets for DAWN
or view top-rated stocks among Wall Street analysts.

How have DAWN shares performed in 2023?

Day One Biopharmaceuticals' stock was trading at $21.52 at the beginning of 2023. Since then, DAWN stock has decreased by 37.8% and is now trading at $13.38.
View the best growth stocks for 2023 here
.

When is Day One Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our DAWN earnings forecast
.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01.

What ETFs hold Day One Biopharmaceuticals' stock?

ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Day One Biopharmaceuticals IPO?

(DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Day One Biopharmaceuticals' stock symbol?

Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol "DAWN."

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (8.98%), Franklin Resources Inc. (4.67%), BlackRock Inc. (4.10%), Braidwell LP (3.87%), State Street Corp (3.86%) and Goldman Sachs Group Inc. (2.75%). Insiders that own company stock include Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends
.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Day One Biopharmaceuticals' stock price today?

One share of DAWN stock can currently be purchased for approximately $13.38.

How much money does Day One Biopharmaceuticals make?

Day One Biopharmaceuticals (NASDAQ:DAWN) has a market capitalization of $1.16 billion. The company earns $-142,180,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Day One Biopharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Day One Biopharmaceuticals?

Day One Biopharmaceuticals' mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is dayonebio.com. The company can be reached via phone at 650-484-0899 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:DAWN) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -